US 12,012,438 B2
Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
Jeffrey Schlom, Potomac, MD (US); and Claudia M. Palena, Potomac, MD (US)
Assigned to The United States of America, as represented by the Secretary, Health and Human Services, Bethesda, MD (US)
Filed by The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed on Jun. 14, 2021, as Appl. No. 17/346,452.
Application 17/346,452 is a division of application No. 16/778,043, filed on Jan. 31, 2020, granted, now 11,034,740.
Application 16/778,043 is a division of application No. 15/749,214, granted, now 10,550,164, issued on Feb. 4, 2020, previously published as PCT/US2016/045289, filed on Aug. 3, 2016.
Claims priority of provisional application 62/200,438, filed on Aug. 3, 2015.
Prior Publication US 2021/0380652 A1, Dec. 9, 2021
Int. Cl. C07K 14/47 (2006.01); A61K 9/127 (2006.01); A61K 38/17 (2006.01); A61K 38/19 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C12N 15/86 (2006.01)
CPC C07K 14/4702 (2013.01) [A61K 9/127 (2013.01); A61K 38/1709 (2013.01); A61K 38/193 (2013.01); A61K 39/0011 (2013.01); A61K 39/001152 (2018.08); A61K 39/00117 (2018.08); A61K 39/001182 (2018.08); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C12N 15/86 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/70 (2013.01); C12N 2710/10043 (2013.01); Y02A 50/30 (2018.01)] 20 Claims
 
1. A Tri-adenovirus serotype 5 (Tri-Ad5) vaccine composition, wherein the Ad5 vector has been modified by removal of early 1 (E1) and early 2b (E2b) gene regions (Ad5 [E1-, E2b-]), comprising equal parts Ad5 [E1-, E2b-] Brachyury, Ad5 [E1-, E2b-] carcinoembryonic antigen (CEA) and Ad5 [E1-, E2b-] mucin (MUC) 1, wherein the Ad5 [E1-, E2b-]-Brachyury vaccine comprises a nucleic acid encoding a protein having the sequence of SEQ ID NO: 3.